Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.

Revenue
+58.0%
EPS
+110.7%
Free cash flow
+411.2%
Total debt
−2.25%

Quarter to September 2026, against a year earlier

224.21 4.23 +1.92%
Market cap
$13.0B
P/E
0.0×
Fwd P/E
−803×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
14.06 13.41 11.33 12.73
P/FCF ratio
269.42 0.00 0.00 0.00
P/Operating CF
251.61 554.57 (498.69) 943.64
P/B ratio
13.53 12.04 9.31 9.84
EV/Sales
14.07 13.51 11.46 12.86
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
269.68 (678.98) (180.03) (167.07)
Current Ratio
4.57 5.04 5.43 4.69
Net Debt/EBITDA
(25.55) 30.16 29.18 1.66
Debt/Equity
0.09 0.10 0.10 0.10
Earnings Yield
(1.79%) (2.33%) (3.05%) (2.89%)
Free Cash Flow Yield
0.37% (0.15%) (0.56%) (0.60%)
Free Cash Flow per Share
0.62 0.21 (0.28) 0.07
Book value per Share
12.14 11.60 11.56 11.47
Free Cash Flow
36.49 12.09 (16.48) 3.93
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026